Pfizer (PFE) CEO Albert Bourla Receives 84 Phantom Shares

What Happened

• Albert Bourla, Chairman & CEO of Pfizer Inc., was granted 84 derivative units (phantom shares) on 2026-07-09 at a reported per-unit value of $24.25, totaling $2,037. This was recorded as an award/acquisition (code A) and represents a non-stock, cash-settled deferred compensation unit rather than an open-market purchase of common shares.

Key Details

• Transaction date and price: 2026-07-09; 84 units at $24.25 each; total value $2,037.
• Shares/units owned after transaction: Not specified in the provided filing.
• Footnotes: F1 — each unit equals one phantom share of common stock; F2 — units were acquired under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and are settled in cash after separation from service; they may be moved into an alternative investment account at any time.
• Filing timeliness: Reported on 2026-07-13 for the 2026-07-09 transaction, which falls within the typical two-business-day SEC Form 4 reporting window.

Context

• These are derivative, cash-settled units (phantom shares) tied to Pfizer common stock value and are compensation rather than direct equity purchases. Such awards are common for executives and do not necessarily signal a near-term buy or sell intent.